Navigation Links
Cardium Reports On Third Quarter 2013 Financial Results And Recent Business Developments
Date:11/19/2013

edient supplier.

The sale of the To Go Brands unit is Cardium's second development and monetization of a portfolio business. Its InnerCool subsidiary was advanced and sold to a U.S. affiliate of Philips for approximately $12.5 million.Financial ReportProduct sales for the three months ended September 30, 2013 totaled $472,000, compared to $5,600 for the same period in 2012.  Product sales for the nine months ended September 30, 2013 were $1.7 million, compared to $39,000 for the nine months ended September 30, 2012.  The increase in product sales was comprised of sales from the Company's To Go Brands health sciences business, which Cardium acquired in late September 2012.Cardium's research and development costs for the third quarter ended September 30, 2013 totaled $0.3 million, and selling, general and administrative expenses were $1.6 million, compared to $0.5 million and $1.4 million, respectively, for third quarter ended September 30, 2012.  For the nine months ended September 30, 2013, research and development costs were $1.6 million, and selling, general and administrative expenses were $5.3 million, compared to $2.1 million and $4.4 million, respectively, for the nine months ended September 30, 2012.  Research and development expenses for the nine months ended September 30, 2013 included milestone payments and out-of-pocket costs for the ASPIRE study and product and testing costs for validating production volume and cost efficiency improvements for Excellagen.

For the three months ended September 30, 2013, the Company reported a net loss of $1.9 million, or $(0.28) per share, when compared to a net loss of $1.9 million, or $(0.32) per share for the three months ended September 30, 2012.  For the nine months ended September 30, 2013, the Company reported a net loss of $6.6 million, or $(0.99) per share, compared to a net loss for the nine months ended September 30, 2012 of $6.4 million, or $(1.10) per share.  As of
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Unusual Trading Activity In Cardium Common Stock
2. Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells
3. Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties
4. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
5. Cardium Completes Preferred Stock Financing
6. Cardium Announces Reverse Stock Split
7. Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
8. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
9. Cardium Announces Generx Publication In Molecular Therapy
10. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
11. Cardium Presents Year-End 2012 Financial Results And Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... DIEGO, July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: ... June 30, 2015. For the second quarter of 2015, the Company ... share, compared to a net loss of $13.4 million, or $0.18 ... six months ended June 30, 2015, the Company reported a net ... to net loss of $25.2 million, or $0.35 loss per share, ...
(Date:7/29/2015)... 29, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... Board of Directors, after careful consideration and with ... advisors, has unanimously rejected the purported revised, highly ... plc (NASDAQ: HZNP ) ("Horizon") to acquire ... an all-stock transaction (the "July 21 Proposal"). ...
(Date:7/29/2015)... The U.S. Food and Drug Administration (FDA) ... Integrated Dual Balloon System, that may help fill a ... obesity and one or more obesity-related conditions, according to ... the nation,s largest organization for bariatric surgeons. ... the FDA has approved this new device for the ...
Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 2American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 3
... /PRNewswire-FirstCall/ --,Wyeth Pharmaceuticals, a division of Wyeth ... clinical study,results on bifeprunox at an international ... an investigational,treatment for adult patients diagnosed with ... lipid profile, similar to,placebo. In addition, increases ...
... 30, 2007 /PRNewswire-FirstCall/ - Helix today,announced positive results ... Interferon Alpha-2b in women with human papilloma virus,(HPV) ... a clinically efficacious response to treatment,in nearly half ... an excellent safety profile, with no significant local,intolerance ...
Cached Medicine Technology:Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 2Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 3Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 4Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 5Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 6
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of its ... to apply lotion or medication to a hard-to-reach area. This invention is patented. , ... to the back, and provides thorough coverage. The product would prevent the user from ...
(Date:7/30/2015)... ... July 30, 2015 , ... After conducting a nationwide executive search led ... Hospital in Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive ... years of healthcare leadership experience, Walsh is an expert in organizational change, physician development, ...
(Date:7/30/2015)... ... 30, 2015 , ... According to Chicago Implant Dentist Dr. ... removable denture acceptable. The demand for dental implants is rising exponentially and is ... loading techniques will have the ability to offer the patient a great service. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Diagnotes, Inc. announced ... for reimbursement from the Centers for Medicare & Medicaid Services (CMS) for the ... experimenting with manual data capture or, in many cases, just deciding it’s too ...
(Date:7/29/2015)... (PRWEB) , ... July 30, 2015 , ... Avid collector, ... Dorton Arena Raleigh North Carolina concert posters. The same poster art was used for ... by Globe Poster based in Baltimore and are classic boxing style concert posters. ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:Diagnotes Announces Expansion of its Mobile Healthcare Communication System to Include Chronic Care Management Reimbursement Support 2Health News:Diagnotes Announces Expansion of its Mobile Healthcare Communication System to Include Chronic Care Management Reimbursement Support 3
... NY, May 5, 2011When children or adolescents with asthma ... it may impair their ability to manage the asthma ... is described in an article in Pediatric Allergy, ... Mary Ann Liebert, Inc. The article is available free ...
... cells have huge potential in medicine because they have the ... (such as nerve cells, muscle cells, and skin cells)potentially providing ... permanently lost by a patient. Stem cells are also relevant ... processes that shape the formation of one cell type versus ...
... News) -- The makers of cold and fever medications that ... discontinue infant-drops versions of the products to avoid confusion that ... Once production ends, later this year, the companies will ... of 12. Companies such as Johnson & Johnson currently sell ...
... [Brown University] Despite evidence that feeding tubes do ... elderly patients with advanced dementia, their frequency of use ... family members finds that discussions surrounding the decision to ... dementia is a terminal illness that often affects a ...
... 5, 2011 Ben-Gurion University of the Negev researcher ... from the Bill & Melinda Gates Foundation to develop ... without the need for blood collection in field settings. ... cellphone and a red laser pointer that can noninvasively ...
... modifications present in breast cancer has revealed potentially important ... researchers have reported. Epigenetics is a term used ... way its code is translated into proteins. These changes ... researchers knew epigenetics was important in cancer, information about ...
Cached Medicine News:Health News:CIRM awards Scripps Research Institute scientists $3.5 million 2Health News:Drugmakers to End Infant Formulas of Products With Acetaminophen 2Health News:Drugmakers to End Infant Formulas of Products With Acetaminophen 3Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Gates Foundation awards Ben-Gurion U. researcher grant for malaria detection using cell phones 2Health News:Epigenetic study reveals new insights into breast cancer 2Health News:Epigenetic study reveals new insights into breast cancer 3
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... D kit is an enzymeimmunoassay for the ... metabolites in serum or plasma. Calibrators, controls ... 25-OH D. The diluted samples are incubated ... a highly specific sheep 25-OH D antibody ...
Medicine Products: